Innate Pharma SA revenue

Innate Pharma SA's revenue was $10.2m in fiscal 2025, down 53.2% on the year before. Since fiscal 2017 ($49.8m) it has grown at a compound -18.0% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Innate Pharma SA: revenue history, annual
Fiscal year	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	50	111	96	80	29	61	67	22	10
Growth on the year before	—	+123.1%	−13.8%	−16.8%	−63.3%	+107.9%	+9.7%	−67.3%	−53.2%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Innate Pharma SA	$10.2m	-53.2%	—
Caribou Biosciences, Inc.	$10.0m	10.0%	-11.0%
Relay Therapeutics, Inc.	$10.3m	23.9%	122.3%
Opus Genetics, Inc.	$9.9m	-36.1%	-39.8%
Mindwalk Holdings Corp.	$11.3m	47.8%	—
Surrozen, Inc.	$11.5m	-8.8%	—

Compare with peers

Head to head: CRBU vs IPHA IPHA vs RLAY IPHA vs IRD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Innate Pharma SA's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Innate Pharma SA.